Not medical advice. This article is about public commentary and public perception of GLP-1 medications. GLP-1 drugs like semaglutide (sold under brand names such as Wegovy and Ozempic) and tirzepatide (sold as Mounjaro and Zepbound) are prescription medications approved for specific medical uses, and any decisions about treatment should be made with a licensed clinician.

Over the past few years, GLP-1 receptor agonists have transformed public conversation about weight management and metabolic health — not only because of clinical data, but also because high-profile individuals have openly discussed them.

Among the most cited voices are Elon Musk, CEO of Tesla and SpaceX, and Michael Rubin, the CEO of sports and ecommerce company Fanatics. In public posts and interviews, both have referenced GLP-1 drugs as part of their personal health narratives — highlighting the medications’ appetite-modulating effects and how they can support weight outcomes when used under supervision.

Musk, for example, shared commentary on social media about using appetite-regulating medications including GLP-1s and making them more affordable, calling them important tools for public health in broad terms. Rubin has similarly talked about how a GLP-1 medication like Ozempic figured into his own experience managing weight.

Why Celebrity Mentions Matter (But Don’t Replace Evidence)

When well-known figures mention specific health interventions, it can have several effects:

1. Increased public awareness – People who never paid attention to medical news may suddenly learn about GLP-1 medications.
2. Heightened interest – Social media posts about these drugs, even in personal or casual contexts, often go viral, prompting public discussion and searches.
3. Potential misunderstanding – Celebrity mentions can inadvertently blur the line between personal narrative and clinical recommendation — even when that is not the intent.

Medical experts emphasize that the approved uses of GLP-1 drugs are specific. For example, semaglutide — the active ingredient in Wegovy, Ozempic, and the oral tablet Rybelsus — is approved in the U.S. to treat type 2 diabetes and, in specific dosing and patient groups, chronic weight management.

These approvals are backed by clinical trials demonstrating average changes in body weight and metabolic outcomes in regulated settings — not just personal anecdotes.

“Musk, Rubin and the GLP-1 Conversation” in Context

News outlets have noted that Musk’s remarks about weight loss drugs helped drive broader public discourse about GLP-1 medications and policy discussion around access and cost. His social media comments have included viewpoints on broad affordability and public health implications of these kinds of therapies.

Rubin’s comments — frequently covered in business and lifestyle outlets — underscore how individual leaders contextualize these medications within their own health journeys, often alongside exercise and nutrition.

Public awareness itself can influence healthcare demand, prescription trends, and even industry strategy, but it’s key to interpret these mentions through a lens of clinical context: celebrity commentary is not a substitute for evidence or guidance from healthcare providers.

Why Clinical Guidance Still Matters Most

GLP-1 medications work by mimicking the body’s glucagon-like peptide-1 hormone, affecting appetite and glucose regulation. While this mechanism has shown benefits in controlled studies, real-world use is guided by clinical criteria such as body mass index (BMI), comorbid conditions, and individual health risks.

Doctors and endocrinologists review patient history, labs, and existing conditions before recommending a specific therapy. They also discuss potential side effects — such as gastrointestinal changes — and long-term management plans.

Part of responsible care is understanding that public figures have very different health profiles and medical oversight than the average person. What one person discusses in a media interview or social media post may not apply to someone else.

Telehealth Providers and Public Demand

As interest in GLP-1 medications has grown, many telehealth platforms have reported increased inquiries and new patient enrollment for weight-management programs that may encompass these medications as part of a comprehensive plan. In industry interviews, leaders in the telehealth space — including the CEO of LevelsRx — have noted rapid year-over-year growth in new user engagement as more people explore telehealth pathways for care.

LevelsRx describes itself as a clinician-guided online weight management program that connects patients with licensed providers, integrates ongoing support, and works through legitimate pharmacies when medication is clinically appropriate. The company reports expanding patient access and rising demand as part of the broader shift toward digital first care models.

Importantly, references to LevelsRx in this context are about healthcare delivery trends, not endorsements or direct claims about medication use. LevelsRx is mentioned here to illustrate how telehealth clinicians are responding to broader public interest — not to suggest where or how readers should obtain access to any drug.

What Readers Should Take Away

Telehealth growth reflects consumer interest in convenience and access but does not replace individualized medical evaluation.

Celebrity and billionaire remarks can raise awareness about medical treatments, but those mentions are personal perspective, not clinical guidance.

GLP-1 medications are prescription drugs with specific approved uses and safety profiles established through regulatory review.

Clinical decisions should always involve a licensed provider, who can interpret individual health needs and evidence-based protocols.